ArticleInvestigative ophthalmology & visual science2025
Association Between Statin Use and Glaucoma Risk: A Population-Based Study.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the association between statin use and glaucoma risk. Methods: This is a nationwide nested case-control study including adults with hyperlipidemia from the Taiwan National Health Insurance Research Database between 2009 and 2020. Cases were individuals newly diagnosed with ocular hypertension, primary open-angle glaucoma (POAG), or normal tension glaucoma (NTG). Controls were individuals without any subtypes of glaucoma. Prescription records for statins, fibrates, and other cholesterol-lowering medications were collected. Logistic regression models were applied to assess the association between medication exposure and the risk of glaucoma. Results: The final analysis included 32,640 participants with ocular hypertension, 20,390 with POAG, 9945 with NTG, and more than 130,560 in the control group. Compared to non-users, statin users had significantly higher risks of developing ocular hypertension (adjusted odds ratio [aOR] = 1.12; 95% confidence interval [CI], 1.09-1.15; P < 0.001) and POAG (aOR = 1.07; 95% CI, 1.04-1.11; P < 0.001), particularly among those prescribed atorvastatin and rosuvastatin. Subgroup analyses by duration of statin prescription (<1 year, 1-3 years, and >3 years) revealed a trend of higher glaucoma risk with longer statin use. Additionally, fibrate use was associated with an increased risk of ocular hypertension (aOR = 1.05; 95% CI, 1.00-1.10; P = 0.032), and POAG (aOR = 1.09; 95% CI, 1.03-1.15; P = 0.002). Conclusions: Statin use, particularly atorvastatin and rosuvastatin, is associated with an increased risk of ocular hypertension and POAG among patients with hyperlipidemia. The risk appears to increase with longer durations of statin use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.